Tessa Andermann

Tessa Andermann, MD, MPH is an Assistant Professor in the Department of Medicine, Division of Infectious Diseases at the University of North Carolina at Chapel Hill School of Medicine. She is a physician-scientist specializing in translational approaches to understand microbially-related complications of hematopoietic stem cell transplantation (HCT) and cellular immunotherapy.

Her research focuses on gut microbiome interactions, particularly host-microbiome mechanisms underlying infections and graft-versus-host disease in cancer patients. She employs advanced sequencing and bioinformatic technologies to investigate these relationships, with recent work examining secondary bile acids in myeloma supported by a CGIBD Pilot/Feasibility Award. Prior to joining UNC in 2019, she developed expertise in gut microbiome research at Stanford under Ami Bhatt.

Her publication record shows a strong focus on microbiome dynamics in transplant settings, antimicrobial resistance, and novel therapeutic interventions. Recent work includes clinical trials of probiotics for COVID-19 exposure and studies on CD30 CAR-T cell therapy complications. Her research bridges clinical infectious diseases with cutting-edge microbiome science.

Scientific Recognition:

• Pilot and Feasibility Award 2022 from the Center for Gastrointestinal Biology and Disease (CGIBD)

Dr. Andermann maintains active collaborations with multidisciplinary mentors including Anthony Fodor and Casey Theriot at CGIBD, as well as experts in microbiology, hematology, oncology, and bioinformatics. She has contributed significantly to Blood and Marrow Transplant Clinical Trials Network publications and serves as a key investigator in several clinical trials examining microbiome interventions in immunocompromised hosts.

Her laboratory work focuses on biorepository development and clinical trial design for microbiome-based interventions, with particular emphasis on translating basic science discoveries into clinical applications for transplant patients.